XALKORI is a kinase inhibitor indicated for the treatment of patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC) that
is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. This indication
is based on response rate. There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.
To report an adverse event or contact the Medical Information organization for additional professional and/or medical resources. Contact Medical Information